The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
Open accessAbstract
Background and Aims: Sustained virologic response (SVR) to interferon (IFN)‐free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into a clinical benefit. We assessed the impact of pretreatment HVPG, changes in HVPG, and posttreatment HVPG on the development of hepatic decompensation in patients with PH who achieved SVR to IFN‐free therapy. Moreover, we evaluated transient elastography (TE) and von Willebrand factor to platelet count ratio (VITRO) as noninvasive methods for monitoring the evolution of PH. Approach and Results: The study comprised 90 patients with HVPG ≥ 6 mm Hg who underwent paired HVPG, TE, and VITRO assessments before (baseline [BL]) and after (follow‐up [FU]) IFN‐free therapy. FU HVPG but not BL HVPG predicted hepatic decompensation (per mm Hg, hazard ratio, 1.18; 95% confidence interval, 1.08‐1.28; P < 0.001). Patients with BL HVPG ≤ 9 mm Hg or patients who resolved clinically significant PH (CSPH) were protected from hepatic decompensation. In patients with CSPH, an HVPG decrease ≥ 10% was similarly protective (36 months, 2.5% vs. 40.5%; P < 0.001) but was observed in a substantially higher proportion of patients (60% vs. 24%; P < 0.001). Importantly, the performance of noninvasive methods such as TE/VITRO for diagnosing an HVPG reduction ≥ 10% was inadequate for clinical use (area under the receiver operating characteristic curve [AUROC], < 0.8), emphasizing the need for HVPG measurements. However, TE/VITRO were able to rule in or rule out FU CSPH (AUROC, 0.86‐0.92) in most patients, especially if assessed in a sequential manner. Conclusions: Reassessment of HVPG after SVR improved prognostication in patients with pretreatment CSPH. An “immediate” HVPG decrease ≥ 10% was observed in the majority of these patients and was associated with a clinical benefit, as it prevented hepatic decompensation. These results support the use of HVPG as a surrogate endpoint for interventions that lower portal pressure by decreasing intrahepatic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183 · cited 2×
“Although new onset of jaundice is commonly referred to as a decompensating event in natural history studies,(31) we did not incorporate jaundice in the definition of hepatic decompensation, because this term is poorly defined.(32) This is in line with previous studies investigating risk factors for hepatic decompensat…”
ResultSanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390
Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“completely protected from hepatic decompensation in the follow-up [96].”
BackgroundEASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationSchwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010060 · Cited by 70
“While etiological therapy is effective to improve PH, as observed after cure of hepatitis C [6], currently there are no drug therapies specifically approved for NASH.”
BackgroundSelf-citationSolà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.009 · Cited by 41
Paternostro, R., Becker, J., Hofer, B. S., Panagl, V., Schiffke, H., Simbrunner, B., Semmler, G., Schwabl, P., Scheiner, B., Bucsics, T., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.09.009 · Cited by 17
Self-citationStift, J., Semmler, G., Wöran, K., Simbrunner, B., Scheiner, B., Schwabl, P., Paternostro, R., Pinter, M., Stättermayer, A. F., Meischl, T., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.08.028 · Cited by 16
Self-citation
Metadata
- Authors
- Mandorfer, M., Kozbial, K., Schwabl, P., Chromy, D., Semmler, G., Stättermayer, A. F., Pinter, M., Hernández‐Gea, V., Fritzer‐Szekeres, M., Steindl‐Munda, P., Trauner, M., Peck‐Radosavljevic, M., García‐Pagán, J. C., Ferenci, P., & Reiberger, T.
- Venue
- Hepatology
- Published
- 2019-10-14
- Volume
- 71
- Issue
- 3
- Pages
- 1023-1036
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2964678848
- Cited by
- 160
- References
- 4
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.